Darolutamide Plus ADT Delivers Significant Benefits for Metastatic Prostate Cancer
Recent findings from the phase 3 ARANOTE trial have highlighted the potential of darolutamide (Nubeqa), an androgen receptor inhibitor, when used in combination with androgen-deprivation therapy (ADT) to treat metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Tian Zhang, associate professor and director of clinical research at UT Southwestern Medical Center, presented a comprehensive review of the trial results during a Community Case Forum in Frisco, Texas. Her analysis focused on both clinical efficacy and real-world considerations for patients beginning treatment.
The ARANOTE trial enrolled patients newly diagnosed with mHSPC who had started hormone deprivation therapy less than 12 weeks prior and had not received second-generation androgen receptor-targeted therapy. All participants demonstrated good performance status and organ function. Patients were stratified according to key factors such as presence of visceral metastases, prior local therapy, and whether their disease was synchronous or metachronous. The primary endpoint of the study was radiographic progression-free survival (rPFS), while overall survival (OS) and several other outcomes—including time to subsequent treatments, time to castration-resistant disease, prostate-specific antigen (PSA) progression, rates of undetectable PSA, pain progression, and safety—were secondary endpoints.
In this global trial, randomization was conducted at a 2:1 ratio, resulting in more patients receiving the combination of darolutamide and ADT compared to ADT with placebo. The study cohort reflected significant diversity: approximately 30% of participants were recruited from Asia, a quarter from Latin America, and about 10% were Black. Notably, 70% of patients had de novo metastatic disease, and 12% exhibited visceral metastases.
Strong Efficacy Data Presented at ESMO 2024
At the European Society for Medical Oncology Congress (ESMO) in 2024, investigators presented compelling efficacy data from the ARANOTE trial. The primary endpoint showed that darolutamide combined with ADT improved median progression-free survival at two years: the two-year PFS rate was 70% for patients on darolutamide and ADT compared to 52% for those receiving ADT with placebo. This difference was statistically significant, with a hazard ratio (HR) of 0.54.
Further analysis by predefined subgroups generally favored the combination therapy across most categories. While some confidence intervals crossed 1.0—particularly among Black patients, those with visceral metastases, and individuals over age 85—the overall trend supported the efficacy of darolutamide plus ADT.
Secondary outcomes reinforced these findings. Time to metastatic castration-resistant disease, time to PSA progression, pain progression, and time to initiation of subsequent treatment all favored the doublet regimen. Time to metastatic castration resistance and time to PSA progression yielded HRs in the range of 0.3 to 0.4. Although pain progression was more subjective with less separation between treatment arms, a notable finding was that 62% of patients on darolutamide plus ADT achieved undetectable PSA levels (<0.2 ng/mL), compared to just 18% in the placebo group.
Navigating Insurance Coverage and Treatment Options for Patients
Dr. Zhang also addressed practical challenges related to insurance coverage when initiating advanced therapies such as darolutamide. For patients with commercial insurance plans, co-pay assistance programs can help mitigate costs. Medicare currently has an annual out-of-pocket cap near $2,000—a significant improvement over previous years—with co-payments typically ranging from $500 to $800 per cycle during the initial months of treatment.
However, ongoing changes in insurance policies may impact future patient expenses. Dr. Zhang emphasized transparency when discussing treatment options with newly diagnosed patients: “There are four approved options for this setting; none have been directly compared head-to-head for efficacy.” She ensures that patients receive clear information about each drug and its potential side effects before beginning therapy—often starting with darolutamide based on tolerability and effectiveness.
Despite these efforts, cost remains a barrier for some individuals. Dr. Zhang advises her patients not to be surprised if adjustments in therapy are needed due to insurance or financial constraints: “If we’re unable to get this because of co-pay costs or other reasons, we’ll consider alternative options.” Her approach reflects a commitment to personalized care while navigating the complexities of modern oncology reimbursement.
YOU MAY ALSO LIKE
Prostate Cancer Awareness: Why a PSA Test Could Save Your Life
Bridgnorth Hosts Large PSA Testing Event to Fight Prostate Cancer
PSA Test Key to Guiding Prostate Cancer Care and Treatment Decisions
